Efficacy and Safety of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in West Africa : A Systematic Review and MetaAnalysis
Abstract
Background : Artemether-lumefantrine (AL) constitutes the artemisinin-based combination therapy (ACT) of first choice of the treatement of uncomplicated Plasmodium falciparum malaria.The study aim to estimate the pooled Adequate Clinical and Parasitological Response (ACPR) rate at day 28 following AL treatment in West Africa, and to characterise systematically the safety and tolerability profile of AL across all included studies.
Methods : Systematic review and meta-analysis following PRISMA 2020 guidelines. Databases searched: PubMed/MEDLINE, Cochrane Library, WHO AFRO repository, ClinicalTrials.gov (last updated May 2026). Eligible study designs included prospective cohort studies, single-arm efficacy studies, and randomised controlled trials with an extractable AL arm. Day-28 PCR-corrected ACPR was pooled as logit-transformed proportions under a DerSimonian-Laird random-effects model.
Results : Ten studies from seven countries, and 2,600 participants were included. The pooled ACPR was 98.7% (95% CI : 97.5–99.3%), with substantial between-study heterogeneity (I² = 60%; Tau² = 0.56) and a 95% prediction interval of 91.6–99.8%. One real-world effectiveness study of unsupervised treatment (Nanoro, Burkina Faso) reported a markedly lower ACPR of 77.8%; including it widened heterogeneity (I² = 94%) and the prediction interval (41.8–100%), reflecting the different construct measured. Adverse events were predominantly mild and transient ; no serious adverse event attributed to AL was reported across studies.
Conclusion : Continuous, protocol-standardised therapeutic efficacy monitoring — particularly in high-transmission settings such as Niger — and attention to treatment adherence are recommended.
Downloads
References
Adjuik, M., Babiker, A., Garner, P., Olliaro, P., Taylor, W., & White, N. (2004). Artesunate combinations for treatment of malaria: A meta-analysis. The Lancet, 363(9402), 9–17. https://doi.org/10.1016/S0140-6736(03)15162-8
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., et al. (2014). Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 371(5), 411–423. https://doi.org/10.1056/NEJMoa1314981
Awodele, O., Bello, I. S., Akodu, B. A., Ahmed, A. A., Usman, S., Bolarinwa, R. A., Akinyede, A., Adelabu, H. A., Akande, E. O., Dey, J., Kudrigikar, V., Rao, P. S., & Mehta, S. (2025). Arterolane and piperaquine vs. artemether and lumefantrine in uncomplicated malaria: A randomized study in Nigeria. International Journal of Infectious Diseases. https://pubmed.ncbi.nlm.nih.gov/41033576/
Bakshi, R., Hermeling-Fritz, I., Gathmann, I., & Alteri, E. (2000). An integrated assessment of the clinical safety of artemether-lumefantrine: A new oral fixed-dose combination antimalarial drug. Transactions of the Royal Society of Tropical Medicine and Hygiene, 94(4), 419–424. https://doi.org/10.1016/s0035-9203(00)90126-3
Basco, L. K. (2004). Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. The American Journal of Tropical Medicine and Hygiene, 70(3), 245–250. https://doi.org/10.4269/ajtmh.2004.70.245
Beavogui, A. H., Camara, A., Delamou, A., Diallo, M. S., Doumbouya, A., Kourouma, K., et al. (2020). Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: An open-label two-arm randomised controlled trial. Malaria Journal, 19, 223. https://doi.org/10.1186/s12936-020-03290-w
Borrmann, S., Sasi, P., Mwai, L., Bashraheil, M., Bhatt, S., Estambale, B., et al. (2011). Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS ONE, 6(11), e26005. https://doi.org/10.1371/journal.pone.0026005
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188. https://doi.org/10.1016/0197-2456(86)90046-2
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., et al. (2009). Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 361(5), 455–467. https://doi.org/10.1056/NEJMoa0808859
Falade, C. O., Dada-Adegbola, H. O., Ogunkunle, O. O., Oguike, M. C., Nash, O., & Ademowo, O. G. (2014). Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo) for the treatment of acute uncomplicated malaria in Nigerian children. Medical Principles and Practice, 23(3), 204–211. https://doi.org/10.1159/000360578
Faucher, J. F., Aubouy, A., Adeothy, A., Cottrell, G., Doritchamou, J., Gourmel, B., et al. (2009). Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated falciparum malaria in Benin: A randomized effectiveness noninferiority trial. The Journal of Infectious Diseases, 200(1), 57–65.
Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., et al. (Eds.). (2022). Cochrane handbook for systematic reviews of interventions (Version 6.3). Cochrane. https://doi.org/10.1002/9781119536604
Kayentao, K., Doumbo, O. K., Pénali, L. K., Offianan, A. T., Bhatt, K. M., Kimani, J., Tshefu, A. K., et al. (2012). Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: A randomised controlled trial. Malaria Journal, 11, 364. https://doi.org/10.1186/1475-2875-11-364
Labor, T. S. A., Komeh, J. P., et al. (2026). Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria among children 6–59 months in three sentinel sites of Sierra Leone, 2021–2022. Malaria Journal. https://doi.org/10.1186/s12936-026-05850-y
Laminou, I. M., Issa, I., Adehossi, E., Maman, K., Jackou, H., Coulibaly, E., et al. (2024). Therapeutic efficacy and tolerability of artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020. Malaria Journal, 23, 144. https://doi.org/10.1186/s12936-024-04945-8
Laminou, I. M., et al. (2025). Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022. Malaria Journal. https://doi.org/10.1186/s12936-025-05679-x
Ndiaye, J. L., Faye, B., Gueye, A., Tine, R., Ndiaye, D., Tchania, C., et al. (2011). Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: A randomised, open-label trial. Malaria Journal, 10, 237. https://doi.org/10.1186/1475-2875-10-237
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Rasheed, A., Khan, S. M., Awan, M. Y., Khurshid, U., & Ahmad, K. (2011). Efficacy and safety of artemether-lumefantrine in uncomplicated falciparum malaria in Liberia. Journal of the Pakistan Medical Association, 61(2), 131–134.
Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P. (2009). Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews, (3), CD007483. https://doi.org/10.1002/14651858.CD007483
Sondo, P., Derra, K., Diallo-Nakanabo, S., Tarnagda, Z., Zampa, O., Kazienga, A., et al. (2015). Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: A randomized open label trial. Malaria Journal, 14, 325. https://doi.org/10.1186/s12936-015-0843-8
Uwimana, A., Legrand, E., Stokes, B. H., Ndikumana, J. M., Warsame, M., Umulisa, N., et al. (2020). Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nature Medicine, 26(10), 1602–1608. https://doi.org/10.1038/s41591-020-1005-2
Wells, G. A., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., et al. (2013). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
WHO Malaria Policy Advisory Group. (2022). Updated WHO recommendations on first-line treatment for uncomplicated falciparum malaria. World Health Organization. https://www.who.int/publications/i/item/9789240050174
World Health Organization. (2009). Methods for surveillance of antimalarial drug efficacy.
World Health Organization. (2013). Emergency response to artemisinin resistance in the Greater Mekong Subregion: Regional framework for action 2013–2015 (WHO/HTM/GMP/2013.2).
World Health Organization. (2015). Guidelines for the treatment of malaria (3rd ed.).
World Health Organization. (2023). World malaria report 2023. https://www.who.int/publications/i/item/9789240086173
Yavo, W., Bla, K. B., Djaman, A. J., Assi, S. B., Basco, L. K., Mazabraud, A., & Koné, M. (2010). In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan, Côte d’Ivoire. African Health Sciences, 10(2), 111–116.
Yavo, W., Faye, B., Kuete, T., Djohan, V., Oga, S. A., Kassi, R. R., et al. (2011). Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malaria Journal, 10, 198. https://doi.org/10.1186/1475-2875-10-198.
Copyright (c) 2026 K.S. Abdoulaye, S.I. Alkassoum, I.T. Emoud, A. Zeidou, A. Sayo
This work is licensed under a Creative Commons Attribution 4.0 International License.
